Plus Therapeutics Appoints Kyle Guse to Board, Strengthens Leadership

Plus Therapeutics, a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system cancers, has appointed biotech industry veteran Kyle Guse to its Board of Directors. Guse will serve as chair of the Audit Committee and as a member of the Compensation Committee, bringing over 30 years of experience in financial, legal, and operational roles, including leadership positions at Atossa Therapeutics and DDC Enterprise Ltd. Company executives expressed confidence that Guse’s expertise will strengthen the board and support the execution of Plus Therapeutics’ business plans, which include advancing product candidates for conditions such as leptomeningeal metastases and recurrent glioblastoma. Guse’s background as a Certified Public Accountant, corporate lawyer, and executive is expected to enhance the company’s governance and oversight. The appointment is part of Plus Therapeutics' broader strategy to reinforce its leadership team and drive shareholder value amid ongoing financial and operational challenges.